Want to see BOLT full AI Analyst Report?
Top Page
Bolt Biotherapeutics
(NASDAQ:BOLT)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-21.67% Downside)
Action:Reiterated
Date:08/19/26
The score is held down primarily by weak financial performance (declining revenue, large ongoing losses, heavy cash burn, and higher leverage with debt exceeding equity). Technicals also weigh negatively due to a clear downtrend (price below key moving averages and negative MACD), despite oversold momentum readings. Valuation contributes only modestly because negative earnings and no dividend yield provide limited support.
Positive Factors
Proprietary Immuno-Oncology Platform
Boltbody provides a defined technology base for developing multiple antibody-based immuno-oncology candidates, potentially supporting pipeline expansion and differentiation if the platform continues to produce clinically viable programs.
Negative Factors
Declining Revenue
The revenue decline and very small revenue base show that Bolt has not established durable commercial scale. This limits internally generated funding and makes future performance highly dependent on clinical progress, partnerships, or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Immuno-Oncology Platform
Boltbody provides a defined technology base for developing multiple antibody-based immuno-oncology candidates, potentially supporting pipeline expansion and differentiation if the platform continues to produce clinically viable programs.
Read all positive factors
Bolt Biotherapeutics (BOLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.16M
Dividend YieldN/A
Average Volume (3M)29.18K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth12.79%
EPS Growth37.93%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.00
Shares Outstanding1,926,345
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside278.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-15.88
Revenue Forecast (FY)$1.13M
Bolt Biotherapeutics Business Overview & Revenue Model
Company Description
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate c...
How the Company Makes Money
As a clinical-stage biotechnology company, Bolt Biotherapeutics has historically generated little to no recurring product revenue and primarily funds operations through external financing. The company’s cash inflows have generally come from (1) ca...
Bolt Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.70M | 7.70M | 7.69M | 7.88M | 5.73M | 1.26M |
| Gross Profit | 4.50M | 6.20M | 7.69M | -53.67M | -67.39M | -74.39M |
| EBITDA | -27.82M | -31.89M | -66.45M | -67.34M | -86.43M | -97.40M |
| Net Income | -28.74M | -33.38M | -63.12M | -69.20M | -88.10M | -98.59M |
Balance Sheet | ||||||
| Total Assets | 40.34M | 56.75M | 99.63M | 159.78M | 227.81M | 307.72M |
| Cash, Cash Equivalents and Short-Term Investments | 17.60M | 27.50M | 47.32M | 102.19M | 168.89M | 186.22M |
| Total Debt | 21.62M | 22.96M | 25.21M | 20.22M | 22.61M | 24.36M |
| Total Liabilities | 27.70M | 30.24M | 42.43M | 47.04M | 56.30M | 57.60M |
| Stockholders Equity | 12.64M | 26.50M | 57.20M | 112.74M | 171.51M | 250.12M |
Cash Flow | ||||||
| Free Cash Flow | -31.54M | -39.92M | -61.33M | -69.73M | -78.46M | -59.40M |
| Operating Cash Flow | -31.45M | -39.85M | -61.29M | -69.53M | -76.50M | -57.07M |
| Investing Cash Flow | 34.65M | 44.30M | 57.58M | 71.04M | 57.86M | -232.20M |
| Financing Cash Flow | 30.00K | 19.00K | 108.00K | 253.00K | 503.00K | 311.11M |
Bolt Biotherapeutics Technical Analysis
Negative
3.83
Price Trends
4.03
Negative
4.41
Negative
4.82
Negative
Market Momentum
-0.22
Positive
31.67
Neutral
11.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 3.83 is above the 20-day moving average (MA) of 3.78, below the 50-day MA of 4.03, and below the 200-day MA of 4.82, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 31.67 is Neutral, neither overbought nor oversold. The STOCH value of 11.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.
Bolt Biotherapeutics Risk Analysis
Bolt Biotherapeutics disclosed 61 risk factors in its most recent earnings report. Bolt Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bolt Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $6.16M | -0.20 | -100.90% | ― | 12.79% | 37.93% | |
44 Neutral | $10.94M | -0.61 | -96.39% | ― | ― | 81.87% | |
43 Neutral | $7.64M | -2.70 | -39.28% | ― | 33.30% | 40.59% | |
43 Neutral | $4.50M | -1.32 | -35.38% | ― | ― | 85.52% | |
39 Underperform | $425.97K | -0.01 | 1211.14% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
BOLT
Bolt Biotherapeutics
3.18
-1.60
-33.54%
ERNA
Eterna Therapeutics
4.25
-34.50
-89.03%
XBIO
Xenetic Biosciences
3.25
0.43
15.25%
MBIO
Mustang Bio
0.57
-1.07
-65.24%
LYRA
Lyra Therapeutics
0.04
-7.06
-99.51%
INAB
IN8bio
1.14
-1.14
-50.00%
Bolt Biotherapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting
Positive
Jun 11, 2026
On June 10, 2026, Bolt Biotherapeutics, Inc. held its 2026 annual meeting of stockholders, at which 877,358 of the 1,921,567 eligible common shares were represented in person or by proxy. Stockholders elected William P. Quinn and Jakob Dupont, M.D...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.